A Method for Selecting Structure-switching Aptamers Applied to a Colorimetric Gold Nanoparticle Assay

Martin, Jennifer A.; Smith, Joshua E.; Warren, Mercedes; Chávez, J.; Hagen, Joshua A.; Kelley‐Loughnane, Nancy

doi:10.3791/52545-v

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from these therapeutic agents, the nanocarriers are being rapidly developed for the detection of tumor markers [ 238 ]. The aptamers have been reported to lack immunogenic toxicity and are easily synthesized [ 239 , 240 ]. Self-assembled polymeric nanoparticles have been synthesized using the PLGA, and PEG and functionalized with Wy5a aptamer for the suppression of PC aggression [ 241 ].…”

Section: Nanotherapiesmentioning

confidence: 99%

Recent advances and future perspectives in the therapeutics of prostate cancer

Varaprasad,

Gupta,

Prasad

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic defects are major factors that determine the aggressiveness and lethality of PC. The African population is at the highest risk of developing high-grade PC. It can be challenging to distinguish between low-risk and high-risk patients due to the slow progression of PC. Prostate-specific antigen (PSA) is a revolutionary discovery for the identification of PC. However, it has led to an increase in over diagnosis and over treatment of PC in the past few decades. Even if modifications are made to the standard PSA testing, the specificity has not been found to be significant. Our understanding of PC genetics and proteomics has improved due to advances in different fields. New serum, urine, and tissue biomarkers, such as PC antigen 3 (PCA3), have led to various new diagnostic tests, such as the prostate health index, 4K score, and PCA3. These tests significantly reduce the number of unnecessary and repeat biopsies performed. Chemotherapy, radiotherapy, and prostatectomy are standard treatment options. However, newer novel hormone therapy drugs with a better response have been identified. Androgen deprivation and hormonal therapy are evolving as new and better options for managing hormone-sensitive and castration-resistant PC. This review aimed to highlight and discuss epidemiology, various risk factors, and developments in PC diagnosis and treatment regimens.

show abstract